2017 ASCO Annual Meeting!
Session: Plenary Session Including the Science of Oncology Award and Lecture
Type: Plenary Session
Time: Sunday June 4, 1:00 PM to 4:00 PM
Location: Hall B1
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
2017 ASCO Annual Meeting
J Clin Oncol 35, 2017 (suppl; abstr LBA4)
Author(s): Mark E. Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine M. Tung, Anne Armstrong, Wenting Wu, Carsten Dietrich Goessl, Sarah Runswick, Pier Franco Conte; Memorial Sloan Kettering Cancer Center, New York, NY; Seoul National University Hospital, Seoul, Korea, Republic of (South); Medical University of Gdańsk, Gdańsk, Poland; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Basser Center, University of Pennsylvania, Philadelphia, PA; National Hospital Organization Osaka National Hospital, Osaka, Japan; Institut Gustave Roussy, Villejuif, France; First Hospital of Jilin University, Changchun, China; Beth Israel Deaconess Medical Center and Dana-Farber Harvard Cancer Center, Boston, MA; The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; AstraZeneca, Gaithersburg, MD; AstraZeneca, Macclesfield, United Kingdom; University of Padova and Istituto Oncologico Veneto IRCCS, Padua, Italy
Background: Olaparib is an oral PARP inhibitor with anti-tumor activity in HER2-negative mBC with a gBRCAm (NCT00494234). OlympiAD (NCT02000622) was a randomized, open-label, phase III study that assessed efficacy and safety of olaparib vs standard single agent chemotherapy treatment of physician’s choice (TPC) in pts with HER2-negative mBC and a gBRCAm. Methods: Pts aged ≥18 y with HER2-negative mBC (hormone receptor positive or triple negative [TN]) and a gBRCAm, who had received ≤2 chemotherapy lines for mBC, were randomized (2:1) to olaparib tablets (300 mg po bid) or TPC (21-day cycles of either capecitabine [2500 mg/m2 po days 1–14], vinorelbine [30 mg/m2 IV days 1 and 8] or eribulin [1.4 mg/m2IV days 1 and 8]). Treatment was continued until objective disease progression (RECIST v1.1) or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review (BICR). Results: 302 pts were randomized (median age 44 y; 50% TN; 71% prior chemotherapy for mBC; 28% prior platinum) of whom 205 received olaparib and 91 received TPC (6 TPC pts were not treated). At 77% data maturity, PFS by BICR was significantly longer in pts treated with olaparib vs TPC (HR 0.58; 95% CI 0.43, 0.80; P=0.0009; 7.0 vs 4.2 months, respectively). Time to second progression (investigator-assessed) was also longer in the olaparib arm (HR 0.57; 95% CI 0.40, 0.83). Objective response rate was 59.9 and 28.8% in olaparib and TPC arms, respectively. Grade ≥3 adverse events (AE) occurred in 36.6 and 50.5% of olaparib and TPC pts, with AEs leading to discontinuation in 4.9 and 7.7% of pts, respectively. Mean change from baseline in global health-related quality of life (HRQoL, EORTC-QLQ-C30) across all timepoints favored olaparib (difference vs TPC 7.5; 95% CI 2.48, 12.44; P=0.0035). Conclusions: Olaparib tablet monotherapy provided a statistically significant and clinically meaningful PFS benefit to HER2-negative mBC pts with a gBRCAm, compared to standard TPC. The safety profile of olaparib was consistent with prior studies. The efficacy benefit was seen beyond the first progression and HRQoL also improved. Clinical trial information: NCT02000622